This bill establishes new regulations regarding the coverage of prescription drugs for the treatment of advanced metastatic cancer and associated conditions, effective January 1, 2025. It prohibits health plans, including those offered to public employees and managed care organizations, from requiring enrollees to fail on a different drug or prove a history of failure before providing coverage for a prescribed drug. The bill specifies that the drugs must be consistent with best practices, supported by peer-reviewed literature, and approved by the FDA.

Additionally, the bill defines "advanced metastatic cancer" as cancer that has spread from its original site to other parts of the body, and "associated condition" as symptoms or side effects that could jeopardize a patient's health if untreated. These provisions aim to ensure timely access to necessary treatments for patients suffering from advanced metastatic cancer without unnecessary barriers.